03:39 AM EDT, 05/30/2024 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) said Wednesday it had received US Food and Drug Administration approval for Austedo XR as a one-pill-per-day treatment option for patients with tardive dyskinesia or patients with Huntington's disease-associated chorea.

The tablets come in four strengths ranging from 30 mg to 48 mg.

Price: 16.54, Change: +0.09, Percent Change: +0.55